VCIM
DSGN icon

Velan Capital Investment Management’s Design Therapeutics DSGN Stock Holding History

Velan Capital Investment Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Hold
20,000
– – 0.13% 38
2025
Q4 		$188K Hold
20,000
– – 0.11% 36
2025
Q3 		$151K Hold
20,000
– – 0.14% 33
2025
Q2 		$67.4K Buy
20,000
+6,000
+43% +$22.5K 0.07% 41
2025
Q1 		$54K Buy
+14,000
New +$66.8K 0.06% 37

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Velan Capital Investment Management's DSGN Position: Q1 2026 in Review

Velan Capital Investment Management held its Design Therapeutics (DSGN) position steady in Q1 2026 at 20,000 shares worth $213K. The position accounts for 0.13% of the portfolio, ranked #38.

Velan Capital Investment Management first reported a position in DSGN in Q1 2025 and has held it in 5 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Velan Capital Investment Management held 20,000 shares of Design Therapeutics worth $213K as of Q1 2026.
  • Velan Capital Investment Management left its Design Therapeutics share count unchanged in Q1 2026.
  • Design Therapeutics made up 0.13% of Velan Capital Investment Management's portfolio in Q1 2026, its #38 holding.
  • Velan Capital Investment Management first reported a position in Design Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.